Although radiolabeled anti-HER2 antibodies, such as 89Zr-trastuzumab or 111In-pertuzumab, show high potential for HER2 molecular imaging, they may not be the best for clinical applications because of their poor pharmacokinetic characteristics and slow tumor uptake [12]. The gene discussed is ERBB2; the disease is neoplasm.